Fermenta Biotech Limited, a pioneer in pharmaceutical and nutritional ingredients; one of the world’s leading manufacturers of Vitamin D3, is pleased to announce that it has received the Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Spray–Dried variant, VITADEE 100 SD – CHOLECALCIFEROL CONCENTRATE (POWDER FORM) 100, 000 IU/g being manufactured at its Kullu, Himanchal Pradesh facility.
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3. The approval underscores Fermenta’s adherence to the stringent European Pharmacopoeial Standards for manufacturing and product quality.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup
Commenting on the achievement, Mr Prashant Nagre, Managing Director of Fermenta, shared:
“As we enter our 75th year, receiving the CEP for VITADEE 100 SD marks a significant milestone for Fermenta. It reinforces our commitment to the benchmarks of regulatory compliance by growing our product portfolio whilst strengthening our position as an established global partner in the field of Vitamin D3. This accreditation also enables us to move further up the value chain and stands as yet another testament to our focus on excellence, innovation, and trust.”
This recognition further enhances Fermenta’s international footprint and our capability to deliver products that meet the highest global quality and regulatory standards. It represents another step forward in our mission to expand our global presence and create meaningful impact across the health and nutrition industry.
Health Technology Insights: SkyMD Opens New Dermatology Clinic in Albuquerque
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
